291.8K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Cuong Viet Do | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 104,502 | 104,502 | - | - | Stock Option (right to buy) | |
| Joanne Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 14,417 | 14,417 | - | - | Stock Option (right to buy) | |
| Joseph M. Palumbo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 15,417 | 15,417 | - | - | Stock Option (right to buy) | |
| Robert J. Hariri | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 21,815 | 21,815 | - | - | Stock Option (right to buy) | |
| Robert J. Hariri | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 49,800 | 49,800 | - | - | Stock Option (right to buy) | |
| Richard J. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 23,155 | 23,155 | - | - | Stock Option (right to buy) | |
| Richard J. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 34,200 | 40,643 (0%) | 0% | 0 | Common Stock | |
| Michael E. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 56,900 | 56,900 | - | - | Stock Option (right to buy) | |
| Michael E. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 23,325 | 23,325 | - | - | Stock Option (right to buy) | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 61,600 | 61,600 | - | - | Stock Option (right to buy) | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 22,690 | 22,690 | - | - | Stock Option (right to buy) | |
| Sigmund Rogich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 32,700 | 36,926 (0%) | 0% | 0 | Common Stock | |
| Sigmund Rogich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 22,070 | 22,070 | - | - | Stock Option (right to buy) | |
| Cuong Viet Do | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 04 Mar 2024 | 10,000 | 435,854 (8%) | 0% | - | Common stock | |
| Cuong Viet Do | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 04 Mar 2024 | 5,000 | 5,000 | - | - | Warrants (right to buy) | |
| Kim Wendy Joanne | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 5,000 | 44,148 (0%) | 0% | 0 | Common Stock | |
| Cuong Viet Do | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.78 per share. | 30 Nov 2023 | 10,000 | 68,759 (1%) | 0% | 1.8 | 17,800 | Common stock |
| Steve Gorlin | Director | Sale of securities on an exchange or to another person at price $ 1.69 per share. | 09 Nov 2023 | 75,680 | 46,358 (0%) | 1% | 1.7 | 127,899 | Common Stock |
| J. Berman Richard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 51,830 | 69,235 (1%) | 0% | 0 | Common Stock | |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 89,750 | 89,750 | - | - | Stock Option (right to buy) | |
| Robert Hariri J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 42,254 | 42,254 (0%) | 0% | 0 | Common Stock | |
| Paul James Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 93,500 | 93,500 | - | - | Stock Option (right to buy) | |
| Rogich Sigmund | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 42,254 | 42,254 (0%) | 0% | 0 | Common Stock | |
| Steve Gorlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 46,358 | 122,038 (2%) | 0% | 0 | Common Stock | |
| Steve Gorlin | Director | Sale of securities on an exchange or to another person at price $ 3.05 per share. | 05 Sep 2023 | 8,560 | 75,680 (1%) | 0% | 3.1 | 26,108 | Common Stock |
| Richard J. Berman | Director | Sale of securities on an exchange or to another person at price $ 3.50 per share. | 22 Aug 2023 | 10,805 | 16,789 (0%) | 0% | 3.5 | 37,827 | Common Stock |
| Cuong Viet Do | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Cuong Viet Do | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 149,500 | 425,854 (8%) | 2% | 0 | Common Stock | |
| Cuong Viet Do | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 41,506 | 271,401 (5%) | 0% | - | Common Stock | |
| Cuong Viet Do | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 41,506 | 83,014 | - | - | Restricted stock units | |
| Joanne Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Joseph M. Palumbo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Richard J. Berman | Director | Sale of securities on an exchange or to another person at price $ 6.50 per share. | 22 May 2023 | 5,000 | 29,194 (0%) | 0% | 6.5 | 32,506 | Common Stock |
| Richard J. Berman | Director | Sale of securities on an exchange or to another person at price $ 5.81 per share. | 22 May 2023 | 5,984 | 23,210 (0%) | 0% | 5.8 | 34,782 | Common Stock |
| Richard J. Berman | Director | Sale of securities on an exchange or to another person at price $ 8.52 per share. | 27 Mar 2023 | 5,000 | 36,807 (0%) | 0% | 8.5 | 42,608 | COMMON STOCK |
| Richard J. Berman | Director | Sale of securities on an exchange or to another person at price $ 8.52 per share. | 27 Mar 2023 | 3,371 | 41,807 (0%) | 0% | 8.5 | 28,711 | COMMON STOCK |
| Richard J. Berman | Director | Sale of securities on an exchange or to another person at price $ 8.52 per share. | 27 Mar 2023 | 2,613 | 34,194 (0%) | 0% | 8.5 | 22,263 | COMMON STOCK |
| Christopher L. Reading | EVP Neuroscience R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 2,476 | 37,148 (0%) | 0% | 6.1 | 15,153 | COMMON STOCK |
| Cuong Viet Do | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 4,953 | 229,895 (4%) | 0% | 6.1 | 30,312 | COMMON STOCK |
| Joanne Wendy Kim | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 2,476 | 39,148 (0%) | 0% | 6.1 | 15,153 | COMMON STOCK |
| Penelope Markham | EVP Liver Cirrhosis R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 2,476 | 47,841 (0%) | 0% | 6.1 | 15,153 | COMMON STOCK |
| Clarence Ahlem | EVP Neuroscience Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 2,476 | 37,148 (0%) | 0% | 6.1 | 15,153 | COMMON STOCK |
| Joseph M. Palumbo | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 2,476 | 37,148 (0%) | 0% | 6.1 | 15,153 | COMMON STOCK |
| Cuong Viet Do | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 16 Feb 2023 | 4,953 | 425,948 (8%) | 0% | 1.2 | 5,845 | Common Stock |
| Cuong Viet Do | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 16 Feb 2023 | 42,000 | 551,948 (10%) | 0% | 0.5 | 19,908 | Common Stock |
| Cuong Viet Do | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 227,000 | 227,000 | - | - | Stock Option (right to buy) | |
| Cuong Viet Do | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 16 Feb 2023 | 4,953 | 430,901 (8%) | 0% | 5.5 | 27,291 | Common stock |
| Cuong Viet Do | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 168,000 | 593,948 (11%) | 3% | 0 | Common Stock | |
| Joanne Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 99,000 | 99,000 | - | - | Stock Option (right to buy) | |
| Joanne Wendy Kim | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 16 Feb 2023 | 2,476 | 41,672 (0%) | 0% | 5.5 | 13,643 | Common Stock |
| Joanne Wendy Kim | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 16 Feb 2023 | 2,476 | 39,196 (0%) | 0% | 1.2 | 2,922 | Common Stock |
| Joanne Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 73,000 | 112,196 (2%) | 1% | 0 | Common Stock | |
| Joanne Wendy Kim | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 16 Feb 2023 | 18,250 | 93,940 (1%) | 0% | 0.5 | 8,651 | Common Stock |
| Joseph M. Palumbo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 156,000 | 156,000 | - | - | Stock Option (right to buy) | |
| Joseph M. Palumbo | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 16 Feb 2023 | 2,476 | 34,672 (0%) | 0% | 5.5 | 13,643 | Common Stock |
| Joseph M. Palumbo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 116,000 | 148,196 (2%) | 2% | 0 | Common Stock | |
| Joseph M. Palumbo | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 16 Feb 2023 | 2,476 | 32,196 (0%) | 0% | 1.2 | 2,922 | Common Stock |
| Joseph M. Palumbo | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 16 Feb 2023 | 29,000 | 119,196 (2%) | 0% | 0.5 | 13,746 | Common Stock |
| Christopher L. Reading | EVP Neuroscience R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 39,624 | 39,624 (0%) | 0% | 0 | COMMON STOCK | |
| Robert J. Hariri | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 34,240 | 34,240 (0%) | 0% | 0 | COMMON STOCK | |
| Terren S. Peizer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 65,000 | 65,000 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Richard J. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 43,578 | 45,178 (0%) | 0% | 0 | COMMON STOCK | |
| Cuong Viet Do | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 79,248 | 234,848 (4%) | 1% | 0 | COMMON STOCK | |
| Steve Gorlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 34,240 | 84,240 (1%) | 0% | 0 | COMMON STOCK | |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 75,000 | 75,000 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 43,578 | 68,622 (1%) | 0% | 0 | COMMON STOCK | |
| Joanne Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 39,624 | 41,624 (0%) | 0% | 0 | COMMON STOCK | |
| Penelope Markham | EVP Liver Cirrhosis R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 39,624 | 50,317 (0%) | 0% | 0 | COMMON STOCK | |
| Sigmund Rogich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 55,000 | 55,000 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Clarence Ahlem | EVP Neuroscience Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 39,624 | 39,624 (0%) | 0% | 0 | COMMON STOCK | |
| Joseph M. Palumbo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 39,624 | 39,624 (0%) | 0% | 0 | COMMON STOCK | |
| Terren S. Peizer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 7,272,728 | 7,272,728 | - | - | Warrants (right to buy) | |
| Terren S. Peizer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 1.65 per share. | 15 Aug 2022 | 3,636,364 | 23,166,210 (445%) | 69% | 1.7 | 6,000,001 | Common Stock |
| Cuong Viet Do | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 124,520 | 124,520 | - | - | Stock Option (right to buy) | |
| Cuong Viet Do | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 124,520 | 124,520 | - | - | Restricted Stock Unit | |
| Robert J. Hariri | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 122,250 | 122,250 | - | - | Stock Option (right to buy) | |
| Richard J. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 129,050 | 129,050 | - | - | Stock Option (right to buy) | |
| Steve Gorlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 122,250 | 122,250 | - | - | Stock Option (right to buy) | |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 130,150 | 130,150 | - | - | Stock Option (Right to buy) | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 127,900 | 127,900 | - | - | Stock Option (right to buy) | |
| Sigmund Rogich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 123,400 | 123,400 | - | - | Stock Option (right to buy) | |
| Jonathan Adams | EVP Liver Cirrhosis Programs | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Feb 2022 | 1,000 | 48,630 (0%) | 0% | 0 | Common Stock | |
| Joseph M. Palumbo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 124,167 | 124,167 | - | - | Stock Option (right to buy) | |
| Joanne Wendy Kim | CFO | Purchase of securities on an exchange or from another person at price $ 5.40 per share. | 07 Dec 2021 | 2,000 | 2,000 (0%) | 0% | 5.4 | 10,798 | Class A common stock, par value $0.0001 |
| Christopher L. Reading | EVP Neuroscience R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 124,167 | 124,167 | - | - | Stock Option (right to buy) | |
| Cuong Viet Do | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 745,000 | 745,000 | - | - | Stock Option (right to buy) | |
| Jonathan Adams | EVP Liver Cirrhosis Programs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 124,167 | 124,167 | - | - | Stock Option (right to buy) | |
| Joanne Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 124,167 | 124,167 | - | - | Stock Option (right to buy) | |
| Penelope Markham | EVP Liver Cirrhosis R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 124,167 | 124,167 | - | - | Stock Option (right to buy) | |
| Clarence Ahlem | EVP Neuroscience Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 124,167 | 124,167 | - | - | Stock Option (right to buy) | |
| Jonathan Adams | EVP Liver Cirrhosis Programs | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jun 2021 | 10,000 | 49,630 (0%) | 0% | 0 | Common Stock | |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 800 | 16,806 | - | - | options | |
| J. Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 800 | 2,400 | - | - | options | |
| Cuong Viet Do | Director | Grant, award, or other acquisition of securities at price $ 3.50 per share. | 30 Jun 2020 | 1,600 | 96,841 (1%) | 0% | 3.5 | 5,600 | Common Stock |
| Cuong Viet Do | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 73,066 | - | - | options | |
| Cuong Viet Do | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 73,866 | - | - | options | |
| Jonathan Adams | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 33,364 | - | - | options | |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 3.50 per share. | 30 Jun 2020 | 1,600 | 20,679 (0%) | 0% | 3.5 | 5,600 | Common Stock |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 16,006 | - | - | options | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 21,988 | - | - | options | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 3.50 per share. | 30 Jun 2020 | 1,600 | 25,044 (0%) | 0% | 3.5 | 5,600 | Common Stock |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 21,188 | - | - | options | |
| J. Wendy Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 1,600 | - | - | options | |
| Penelope Markham | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 3,200 | - | - | options | |
| Cuong Viet Do | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 01 Jul 2018 | 86,666 | 86,666 (0%) | 0% | 1.5 | 129,999 | Preferred Stock |
| Cuong Viet Do | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2018 | 8,666,666 | 9,033,333 | - | - | Warrants | |
| Jonathan Adams | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 01 Jul 2018 | 10,000 | 10,000 (0%) | 0% | 1.5 | 15,000 | Preferred Stock |
| Jonathan Adams | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2018 | 1,000,000 | 4,022,727 | - | - | Warrants | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2018 | 2,000,000 | 2,548,485 | - | - | Warrants | |
| James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 01 Jul 2018 | 20,000 | 20,000 (0%) | 0% | 1.5 | 30,000 | Preferred Stock |
| Mina Sooch | Director | Grant, award, or other acquisition of securities at price $ 0.02 per share. | 02 Jan 2018 | 150,000 | 613,636 (11%) | 0% | 0.0 | 3,600 | common stock |
| Mina Sooch | Director | Grant, award, or other acquisition of securities at price $ 0.15 per share. | 02 Jan 2018 | 200,000 | 463,636 (8%) | 0% | 0.2 | 30,000 | common stock |
| Julie Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 50,000 | 50,000 | - | - | Warrants | |
| Julie Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.15 per share. | 02 Jan 2018 | 200,000 | 300,000 (5%) | 0% | 0.2 | 30,000 | common stock |
| Julie Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.02 per share. | 02 Jan 2018 | 68,500 | 368,500 (7%) | 0% | 0.0 | 1,096 | common stock |
| Julie Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 100,000 | 200,000 | - | - | options | |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 02 Jan 2018 | 16,666 | 16,666 (0%) | 0% | 1.5 | 24,999 | preferred stock |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.15 per share. | 02 Jan 2018 | 200,000 | 268,181 (5%) | 0% | 0.2 | 30,000 | common stock |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.02 per share. | 02 Jan 2018 | 250,000 | 518,181 (9%) | 0% | 0.0 | 4,500 | common stock |
| Michael Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 1,666,000 | 1,666,000 | - | - | Warrants | |
| R. Richard Wieland | interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2017 | 150,000 | 250,000 | - | - | options | |
| Cuong Viet Do | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 100,000 | 100,000 | - | - | options | |
| Cuong Viet Do | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 166,667 | 266,667 | - | - | Warrants | |
| Cuong Viet Do | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 100,000 | 366,667 | - | - | options | |
| Cuong Viet Do | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 200,000 | 2,871,354 | - | - | common stock | |
| Cuong Viet Do | None | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Dec 2016 | 166,667 | 3,038,021 | - | - | common stock | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 100,000 | 225,000 | - | - | options | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 56,818 | 281,818 | - | - | Warrants | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 166,667 | 448,485 | - | - | Warrants | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 100,000 | 548,485 | - | - | options | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 113,636 | 363,636 | - | - | common stock | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 166,667 | 530,303 | - | - | common stock | |
| James Paul Lang | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2016 | 200,000 | 730,303 | - | - | common stock | |
| Jonathan Adams | Director, chief operating officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2016 | 22,727 | 3,022,727 | - | - | Warrants | |
| Jonathan Adams | Director, chief operating officer | Other type of transaction at price $ 0.00 per share. | 11 Apr 2016 | 310,000 | 5,858,067 | - | - | common stock | |
| Jonathan Adams | Director, chief operating officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2016 | 45,454 | 5,903,521 | - | - | common stock | |
| Jonathan Adams | Director, chief operating officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2016 | 200,000 | 6,103,521 | - | - | common stock |